Ketamine Hameln Pharma (Ketamine Hydrochloride)

Ketamine acts as a non‑competitive antagonist at the N‑methyl‑D‑aspartate (NMDA) receptor in the central nervous system. By blocking this excitatory glutamate receptor, it reduces neuronal firing, producing dissociative anesthesia, analgesia, and a trance‑like state. The inhibition of NMDA‑mediated transmission also contributes to its sympathomimetic effects and prevents central sensitization to pain.

The specific dose of Ketamine Hameln Pharma is determined by the prescribing clinician based on the patient’s age, weight, clinical condition, and the intended use (e.g., induction, sedation, or analgesia). Dosage regimens are individualized and must follow local guidelines and the product’s prescribing information.

Safety of ketamine during pregnancy and lactation has not been fully established. It is classified as a category C or unknown drug in many jurisdictions, meaning it should be used only if the potential benefit justifies the potential risk to the fetus or infant. Clinicians should evaluate each case carefully.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details, and any necessary import documentation.

The primary alternative to ketamine for induction and sedation is propofol, a GABA‑ergic agent. Unlike propofol, ketamine preserves airway reflexes and provides analgesia, but may cause emergence phenomena and cardiovascular stimulation. Choice between them depends on the clinical scenario, patient comorbidities, and desired hemodynamic profile. Both agents have distinct safety and efficacy profiles.

Ketamine Hameln Pharma should be stored at ambient temperature, below 25 °C, in its original sealed container. Protect the product from direct sunlight, moisture, and extreme temperature fluctuations. Before use, inspect the vial for particulate matter or discoloration, and ensure aseptic technique when drawing the solution for intramuscular or intravenous administration.

The product is supplied as a sterile injectable solution for intramuscular (IM) or intravenous (IV) administration. The route, volume, and rate of injection are determined by the prescriber based on the intended indication—rapid IV bolus for induction of anesthesia, slower IV infusion for sedation, or IM injection for field use. Proper aseptic technique and monitoring are essential during administration.

The most serious adverse events associated with ketamine include respiratory depression, severe hypertension or tachycardia, emergence reactions such as vivid hallucinations or agitation, and rare cardiac arrhythmias. Clinicians should monitor airway, breathing, circulation, and mental status continuously, especially during induction and the early recovery period, and be prepared to manage these complications promptly.

Ketamine is contraindicated or should be used with extreme caution in patients with uncontrolled hypertension, severe coronary artery disease, elevated intracranial pressure, known hypersensitivity to ketamine or its excipients, and those with a history of psychosis or severe psychiatric disorders that may predispose to emergence phenomena. Pregnant or lactating women should only receive it when benefits outweigh potential risks, and pediatric use requires specialist supervision.